Capital Wealth Planning LLC Has $249,000 Position in Celgene Corporation (CELG)

Capital Wealth Planning LLC held its stake in shares of Celgene Corporation (NASDAQ:CELG) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,000 shares of the biopharmaceutical company’s stock at the close of the first quarter. Capital Wealth Planning LLC’s holdings in Celgene Corporation were worth $249,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. ARS Investment Partners LLC bought a new position in shares of Celgene Corporation in the 1st quarter valued at $222,000. SG Americas Securities LLC increased its stake in shares of Celgene Corporation by 205.4% in the 1st quarter. SG Americas Securities LLC now owns 140,738 shares of the biopharmaceutical company’s stock valued at $17,512,000 after purchasing an additional 274,314 shares during the last quarter. Glenview Trust Co increased its stake in shares of Celgene Corporation by 5.4% in the 1st quarter. Glenview Trust Co now owns 70,484 shares of the biopharmaceutical company’s stock valued at $8,771,000 after purchasing an additional 3,628 shares during the last quarter. Stifel Financial Corp increased its stake in shares of Celgene Corporation by 2.8% in the 1st quarter. Stifel Financial Corp now owns 1,215,960 shares of the biopharmaceutical company’s stock valued at $151,182,000 after purchasing an additional 32,748 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. increased its stake in shares of Celgene Corporation by 10.0% in the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 58,050 shares of the biopharmaceutical company’s stock valued at $7,223,000 after purchasing an additional 5,272 shares during the last quarter. Institutional investors own 79.43% of the company’s stock.

Celgene Corporation (CELG) traded up 1.02% on Friday, reaching $142.04. The company had a trading volume of 5,983,997 shares. Celgene Corporation has a one year low of $96.93 and a one year high of $142.69. The firm has a market capitalization of $111.12 billion, a price-to-earnings ratio of 43.99 and a beta of 1.89. The company’s 50 day moving average is $134.97 and its 200-day moving average is $127.46.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same period last year, the business posted $1.44 earnings per share. Celgene Corporation’s quarterly revenue was up 18.7% compared to the same quarter last year. On average, equities research analysts expect that Celgene Corporation will post $7.33 earnings per share for the current fiscal year.

CELG has been the topic of several recent analyst reports. Robert W. Baird reiterated an “outperform” rating and issued a $162.00 price target on shares of Celgene Corporation in a research note on Monday, May 22nd. BMO Capital Markets restated an “outperform” rating and set a $152.00 price objective on shares of Celgene Corporation in a research report on Tuesday, May 23rd. Credit Suisse Group set a $148.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a research report on Monday, May 22nd. Canaccord Genuity set a $156.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a research report on Monday, May 22nd. Finally, Cantor Fitzgerald set a $160.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a research report on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the stock. Celgene Corporation presently has an average rating of “Buy” and an average price target of $149.34.

ILLEGAL ACTIVITY NOTICE: “Capital Wealth Planning LLC Has $249,000 Position in Celgene Corporation (CELG)” was originally reported by BBNS and is the property of of BBNS. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://baseballnewssource.com/markets/celgene-corporation-celg-stake-maintained-by-capital-wealth-planning-llc/1566103.html.

In other news, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the transaction, the director now directly owns 69,424 shares in the company, valued at $9,061,220.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of Celgene Corporation stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the transaction, the director now owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The disclosure for this sale can be found here. Insiders have sold 267,476 shares of company stock valued at $35,812,841 over the last quarter. Company insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Cleveland Indians Winning Streak Reaches 18
Cleveland Indians Winning Streak Reaches 18


Leave a Reply

 
© 2006-2017 BBNS.